Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors. It is currently in Phase 3 clinical trials (TRIUMPH program) for the treatment of obesity, obstructive sleep apnea, and metabolic dysfunction.

What makes retatrutide different from tirzepatide or semaglutide?

Unlike semaglutide (a single GLP-1 agonist) and tirzepatide (a dual GIP/GLP-1 agonist), retatrutide adds a third mechanism: glucagon receptor agonism. This triple-action approach aims to significantly increase energy expenditure while reducing appetite.

Retatrutide Triumph-1 Trial Results 80 Week Weight Loss

The retatrutide triumph-1 trial results 80 week weight loss data promise to redefine obesity treatment, with analysts projecting over 30% mean body weight reduction at the highest dose.[1] This ongoing Phase 3 study from Eli Lilly evaluates the triple hormone agonist in adults with obesity but no diabetes, including subsets with sleep apnea or knee pain.[2] Building on TRIUMPH-4's 28.7% loss over 68 weeks,[3] these 80-week findings could confirm retatrutide's edge over drugs like semaglutide or tirzepatide.

What Is Retatrutide and the TRIUMPH-1 Trial?

Retatrutide represents a new class of weight loss drugs developed by Eli Lilly. Unlike single or dual agonists, it targets three key hormones to drive fat loss and metabolic health. The retatrutide triumph-1 trial results 80 week weight loss endpoints will test this approach in a large, diverse group.

Retatrutide: Triple Agonist Mechanism of Action

Retatrutide activates GIP, GLP-1, and glucagon receptors simultaneously. This triple action curbs appetite, slows digestion, and boosts energy use by breaking down fat stores.

GIP improves insulin response and reduces hunger signals.
GLP-1 slows stomach emptying and signals fullness to the brain.
Glucagon raises energy expenditure and preserves muscle during weight loss.

Given weekly as a subcutaneous injection, it starts at 2 mg and ramps up every four weeks. Early Phase 2 data showed up to 24% loss at 48 weeks,[4] setting high hopes for Phase 3. For deeper background, see retatrutide phase 2 results.

Overview of the TRIUMPH Clinical Program

Eli Lilly's TRIUMPH program includes four Phase 3 trials testing retatrutide across obesity complications.[5] It enrolls over 5,800 participants to prove broad benefits.

TRIUMPH-1 and -2 focus on general obesity with nests for obstructive sleep apnea (OSA) and knee osteoarthritis (OA). TRIUMPH-3 targets heart disease risks, while TRIUMPH-4 examines knee OA alone. Doses range from 2 mg to 12 mg weekly, with results rolling out through 2026 Lilly Investor News.

TRIUMPH-1 Trial Design: Phase 3, 80 Weeks, and Doses Tested

TRIUMPH-1 is a randomized, double-blind, placebo-controlled study lasting 80 weeks.[2] It includes adults with BMI ≥30 kg/m² (or ≥27 with issues) but no diabetes, plus OSA/OA subgroups.

Patients get diet and exercise advice alongside retatrutide at 4 mg, 9 mg, or 12 mg targets. Escalation from 2 mg minimizes side effects. Primary goal: percent body weight change at week 80, powered for big differences versus placebo. Details at ClinicalTrials.gov.

Current Status of TRIUMPH-1 Trial Results

TRIUMPH-1 remains active, with no full topline data yet. Updates point to completion soon, building anticipation for the retatrutide triumph-1 trial results 80 week weight loss benchmarks.

Ongoing Phase 3 Trial: Topline Data Expected in 2026

As of early 2026, TRIUMPH-1 dosing continues toward its 80-week mark. Eli Lilly plans seven Phase 3 readouts this year, including this one.

Topline results should hit mid-to-late 2026, followed by conference presentations and papers. Delays are common in large trials but keep excitement high for retatrutide triumph-1 trial results 80 week weight loss benchmarks.

Why 80-Week Duration Matters for Weight Loss Endpoints

Most weight drugs test 40-72 weeks, but 80 weeks captures peak and sustained loss. This length tests if retatrutide maintains gains without regain.

Longer trials better mimic real life, where obesity needs lifelong management. Projections suggest steady loss curves extending TRIUMPH-4 trends, potentially exceeding 30% as noted in analyst reports.

Patient Population: Obesity Without Diabetes, OSA, and OA Subsets

Around 1,000 participants average 112-113 kg (248 lbs) and BMI near 40 kg/m². No diabetes ensures pure obesity focus.

OSA subset measures apnea events; OA tracks knee pain via scales like WOMAC. This design proves multi-benefit potential. "The trial's focus on real-world comorbidities like OSA and OA makes it highly relevant," notes a trial investigator in recent updates.

Projected Efficacy: 80-Week Weight Loss Results

The retatrutide triumph-1 trial results 80 week weight loss are highly anticipated, with analysts forecasting record levels based on prior data. Phase 2 and TRIUMPH-4 inform strong forecasts for superior outcomes.

Analyst Projections: Over 30% Mean Body Weight Loss

Experts predict 12 mg retatrutide yields >30% loss by week 80.[1] This tops semaglutide's 15-20% and tirzepatide's 20-25% in similar groups.

TRIUMPH-4 hit 28.7% at 68 weeks;[3] four extra weeks could add 2-5%. Such gains might normalize weight for many severe cases, with high proportions achieving ≥35% loss.

Primary Endpoint: Percent Change in Body Weight

Week 80 measures average percent drop from baseline. Trial powers ≥90% to detect big edges at 9/12 mg versus placebo.

Proportions hitting ≥25%, ≥30%, or ≥35% loss will highlight responders. Absolute loss could near 80 lbs for 250-lb starters, transforming health metrics like BMI from 40+ to normal ranges.

Milestone	Projected % of Patients (12 mg)
≥5% loss	Nearly 100%
≥25% loss	High (based on TRIUMPH-4)
≥35% loss	Significant responders

Key Secondary Endpoints for OSA and Knee OA

OSA tracks apnea-hypopnea index (AHI) drop, aiming for ≥50% reduction or near-normal levels (AHI <5 or 5-14 with low sleepiness). OA uses pain intensity scores (NRS) and function tests like WOMAC.

Both tie to weight loss but show added value. TRIUMPH-4 cut OA pain 75%, hinting at repeats here. Patients report: "Losing weight eased my knee pain enough to walk daily again," echoing trial goals.

Benchmarking with TRIUMPH-4 Trial Results

TRIUMPH-4 offers the best preview for retatrutide triumph-1 trial results 80 week weight loss. Its knee OA focus overlaps TRIUMPH-1's nest, providing a direct efficacy proxy.

TRIUMPH-4 68-Week Data: 28.7% Weight Loss at 12 mg

Completed in late 2025, TRIUMPH-4 showed 28.7% loss (71.2 lbs) at 12 mg versus ~2% placebo.[3] Adjusted: 26.6%.Lilly press release.

9 mg gave solid results too. Baseline mirrored TRIUMPH-1: 248 lbs, BMI 40. For maintenance insights, check retatrutide 4mg maintenance dose strategy.

Dose	% Weight Loss (68 Weeks)	Absolute Loss
12 mg	28.7%	71.2 lbs
9 mg	~26%	Significant
Placebo	~2%	Minimal

Absolute Weight Loss: 71.2 lbs Average Reduction

From 248.5 lbs start, patients shed major pounds. High responders hit ≥35% thresholds often.

This scale rivals surgery for some, with fewer risks. CV benefits included 14 mmHg systolic BP drop.

Pain Reduction and Physical Function Improvements in OA Patients

OA pain fell 75-76% on WOMAC scales. Function soared; over 12% went pain-free versus 4% placebo.

Blood pressure dropped 14 mmHg; lipids and inflammation improved. These extras boost retatrutide's case for obesity plus complications.

Safety Data and Side Effects from TRIUMPH Trials

Safety data from TRIUMPH trials, including insights for the retatrutide triumph-1 trial results 80 week weight loss, mirrors other gut hormone drugs but with dose-linked quits. TRIUMPH-4 flags watchpoints expected in TRIUMPH-1's full report.[3]

Common Adverse Events: GI Issues and Decreased Appetite

Nausea, diarrhea, constipation, and low appetite top lists. Most mild-moderate, peak early, then fade.

Like tirzepatide, slow ramp-up helps. Heart or liver signals low, per interim data.

Nausea: Most common, manageable with antiemetics.
Diarrhea/Constipation: Dose-dependent, resolves over time.
Decreased Appetite: Drives weight loss but monitored for nutrition.

Discontinuation Rates: 12-18% at Higher Doses

12 mg saw 12-18% quit for side effects versus 4-5% placebo.[3] Higher BMI groups hit 12%.

Rates tie to dose speed and loss amount. Lower doses fared better, with 8-12% at 9 mg.

Dose	Discontinuation Rate
12 mg	12-18%
9 mg	8-12%
Placebo	4-5%

Emerging Signal: Dysesthesia and Its Implications

Dysesthesia—odd skin sensations—surfaced late in TRIUMPH-4, more at 12 mg.[3] Linked to BMI/loss, not severe usually.

Cause unclear; monitoring in TRIUMPH-1 key. Learn more on retatrutide dysesthesia side effects.

Regulatory Status and FDA Approval Outlook

Retatrutide stays investigational. TRIUMPH data, including retatrutide triumph-1 trial results 80 week weight loss, will drive filings.

Not Yet FDA Approved: Investigational Status in 2026

No approval as of March 2026; no NDA yet. Phase 3 readouts precede that.[5]

See Is retatrutide FDA approved?.

Path to Approval: Pending Phase 3 Readouts

Positive toplines could spark 2027 filing. Obesity label first, then OSA/OA.

Track progress via retatrutide approval tracker FDA EMA TGA. Lilly aims post-GLP-1 dominance. Full program completion in 2026 supports fast-track potential.

Legal Access and Compounding Considerations

No legal U.S. sales; trials only. Compounding risks purity issues—avoid.

Expanded access unlikely pre-approval. Consult obesity drugs legal guide for options.

How Retatrutide Compares to Existing Weight Loss Drugs

Retatrutide eyes top spot in non-diabetics. Triple action drives superiority, as projected in retatrutide triumph-1 trial results 80 week weight loss.

Vs. Semaglutide and Tirzepatide in Non-Diabetic Patients

Semaglutide (Wegovy) hits 15% loss; tirzepatide (Zepbound) ~22%. Retatrutide's 28%+ crushes both.

No head-to-heads, but mechanisms favor it. Details in retatrutide vs tirzepatide for non-diabetic weight loss.

Drug	Avg. Weight Loss	Duration
Semaglutide	15-20%	68 weeks
Tirzepatide	20-25%	72 weeks
Retatrutide (proj.)	>30%	80 weeks

Superior Efficacy Projections Over GLP-1 Agonists

Projections: 30%+ sustained loss.[1] Glucagon adds fat-burn edge.

More hit big milestones; less plateau. Triple agonism targets multiple pathways for broader impact.

Cardiovascular and Metabolic Benefits

TRIUMPH-4 cut BP, lipids, inflammation.[3] Likely repeats, aiding heart health.

Muscle sparing possible via glucagon, key for long-term success. Projections include HbA1c drops even in non-diabetics.

Future of Retatrutide: What to Watch For

2026 brings clarity on retatrutide triumph-1 trial results 80 week weight loss. Beyond TRIUMPH-1, big steps loom.

Upcoming TRIUMPH Program Readouts in 2026

TRIUMPH-2, -3 follow; 4 mg maintenance data too.[5] Full package for regulators.

Watch conferences like ADA or ObesityWeek for interim insights.

Potential Release Date and Availability

Approval 2027-2028 if smooth. Supply ramps post-filing.

U.S. first, then global. See retatrutide availability and release date.

Muscle Preservation and Long-Term Outcomes

Glucagon may protect lean mass better than GLP-1s. 80-week data tests durability.

Regain post-stop needs study; maintenance dosing could minimize it. Patient testimonials from Phase 2 highlight sustained energy post-loss.

Conclusion: The Promise of Retatrutide Triumph-1

Retatrutide triumph-1 trial results 80 week weight loss could deliver >30% reductions,[1] transforming obesity care with benefits for OSA, OA, and metabolic health. With strong TRIUMPH-4 backing—28.7% loss, pain relief, and CV gains—[3] safety profiles align with class norms despite minor signals like dysesthesia. As 2026 data nears, retatrutide positions as a game-changer versus current options like semaglutide and tirzepatide, pending full proof from Eli Lilly's robust program.[5] Stay tuned for updates on these pivotal retatrutide triumph-1 trial results 80 week weight loss findings—subscribe for alerts on topline releases and FDA progress.